Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL307368 | 1.00 | — | — | |
| SCHEMBL29389744 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TSHRKEAP1NFE2L2 | |
| SCHEMBL4971363 | 0.88 | — | — | |
| SCHEMBL20796 | 0.88 | — | — | |
| SCHEMBL4748477 | 0.88 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2TSHRKEAP1NFE2L2 | |
| Ammonia Solution, Strong SCHEMBL49807 | 0.84 | — | — | |
| SCHEMBL17289281 | 0.84 | — | — | |
| SCHEMBL6726489 | 0.84 | — | — | |
| SCHEMBL8475485 | 0.84 | — | — | |
| Water SCHEMBL6169197 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107954845-B | Process for purifying 4-hydroxyacetophenone | 西姆莱斯有限公司 | 2022-08-19 | — | — | CN | claimed |
| US-10981854-B2 | Method for purification of 4-hydroxyacetophenone | SYMRISE AG (DE) | 2021-04-20 | — | — | US | claimed |
| US-20210002200-A1 | METHOD FOR PURIFICATION OF 4-HYDROXYACETOPHENONE | SYMRISE AG (DE) | 2021-01-07 | — | — | US | claimed |
| US-10752571-B2 | Method for purification of 4-hydroxyacetophenone | SYMRISE AG (DE) | 2020-08-25 | — | — | US | claimed |
| US-20200039911-A1 | METHOD FOR PURIFICATION OF 4-HYDROXYACETOPHENONE | SYMRISE AG (DE) | 2020-02-06 | — | — | US | claimed |
| US-11820752-B2 | Process for the preparation of apalutamide | OLON S.P.A. (IT) | 2023-11-21 | — | — | US | disclosed |
| CN-117062796-A | Crystallization of 4-hydroxyacetophenone using ethanol and ethyl acetate | 西姆莱斯有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-3802515-B1 | PROCESS FOR THE PREPARATION OF APALUTAMIDE | OLON SPA (IT) | 2023-05-10 | — | — | EP | disclosed |
| CN-107954845-B | Process for purifying 4-hydroxyacetophenone | 西姆莱斯有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-20210206742-A1 | PROCESS FOR THE PREPARATION OF APALUTAMIDE | OLON S.P.A. (IT) | 2021-07-08 | — | — | US | disclosed |
| US-10981854-B2 | Method for purification of 4-hydroxyacetophenone | SYMRISE AG (DE) | 2021-04-20 | — | — | US | disclosed |
| EP-2118074-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-11-18 | — | — | EP | disclosed |
| EP-1427697-B1 | SULPHONATION OF PHENOLS | GREAT LAKES CHEMICAL EUROP (CH) | 2008-12-24 | — | — | EP | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| WO-2008092231-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2008-08-07 | — | — | WO | disclosed |
| US-6936732-B2 | Sulphonation of phenols | ADDIVANT USA, LLC | 2005-08-30 | — | — | US | disclosed |
| US-20050054876-A1 | Sulphonation of phenols | ADDIVANT USA, LLC | 2005-03-10 | — | — | US | disclosed |
| EP-1427697-A1 | SULPHONATION OF PHENOLS | Great Lakes Chemical (Europe) GmbH (CH) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003027063-A1 | SULPHONATION OF PHENOLS | GREAT LAKES CHEMICAL (EUROPE) GMBH (CH) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054876-A1 | Sulphonation of phenols | CBR3, C1S, C1R | ALDH1A1 3616/4885SMN1; SMN2 4730/4885TSHR 329/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885SMN1; SMN2 3476/4885TSHR 3859/4885 |
| US-11820752-B2 | Process for the preparation of apalutamide | AR, GNRHR, ACP3 | ALDH1A1 1972/4885SMN1; SMN2 4645/4885TSHR 907/4885 |
| US-20210206742-A1 | PROCESS FOR THE PREPARATION OF APALUTAMIDE | AR, GNRHR, ACP3 | ALDH1A1 1972/4885SMN1; SMN2 4645/4885TSHR 907/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | ALDH1A1 1784/4885SMN1; SMN2 4696/4885TSHR 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.